Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2013


#164384

168pages

Global Markets Direct

$ 2000

In Stock


Global Markets Directs, 'Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with latest updates, and special features on late-stage and discontinued projects. 

It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope


  • A snapshot of the global therapeutic scenario for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer.
  • A review of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy


  • Identify and understand important and diverse types of therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 5
Introduction 7
Global Markets Direct Report Coverage 7
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer 9
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics under Development by Companies 11
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Pre-Clinical Stage Products 18
Comparative Analysis 18
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics - Products under Development by Companies 19
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics - Products under Investigation by Universities/Institutes 22
Companies Involved in Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Development 23
Bristol-Myers Squibb Company 23
Johnson & Johnson 24
AstraZeneca PLC 25
Eli Lilly and Company 26
Genentech, Inc. 27
Bavarian Nordic A/S 28
Merck & Co., Inc. 29
Takeda Pharmaceutical Company Limited 30
Millennium Pharmaceuticals, Inc. 31
Novartis AG 32
GTx, Inc. 33
Teva Pharmaceutical Industries Limited 34
Progenics Pharmaceuticals, Inc. 35
Exelixis, Inc. 36
Aduro BioTech 37
Merck KGaA 38
Active Biotech AB 39
Oncothyreon Inc 40
Medivation, Inc. 41
Oncogenex Pharmaceuticals, Inc. 42
Synta Pharmaceuticals Corp. 43
Nerviano Medical Sciences S.r.l. 44
GenSpera, Inc. 45
Bellicum Pharmaceuticals, Inc. 46
TRACON Pharmaceuticals, Inc. 47
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics Assessment 48
Assessment by Monotherapy Products 48
Assessment by Combination Products 49
Assessment by Route of Administration 50
Assessment by Molecule Type 52
Drug Profiles 54
ipilimumab - Drug Profile 54
DI-17-E-6 - Drug Profile 56
orteronel - Drug Profile 58
cixutumumab - Drug Profile 60
PSMA ADC - Drug Profile 62
GTx-758 - Drug Profile 64
ridaforolimus - Drug Profile 65
tasquinimod - Drug Profile 69
enzalutamide - Drug Profile 71
cabozantinib - Drug Profile 73
ganetespib - Drug Profile 75
rilimogene galvacirepvec - Drug Profile 78
PX-866 - Drug Profile 79
carlumab - Drug Profile 81
bevacizumab + thalidomide + [docetaxel] + [prednisone] - Drug Profile 83
G-202 - Drug Profile 84
BMTP-11 - Drug Profile 86
BPX-101 + [AP-1903] - Drug Profile 87
cediranib maleate + [prednisone] - Drug Profile 89
buparlisib - Drug Profile 90
custirsen sodium + [docetaxel] - Drug Profile 93
TRC-105 - Drug Profile 95
vandetanib + [bicalutamide] - Drug Profile 97
enzastaurin hydrochloride + [docetaxel] + [prednisone] - Drug Profile 99
bortezomib + [mitoxantrone hydrochloride] - Drug Profile 100
cixutumumab + [mitoxantrone hydrochloride] + [prednisone] - Drug Profile 101
custirsen sodium + [docetaxel] + [prednisone] - Drug Profile 102
danusertib - Drug Profile 104
OGX-427 + [prednisone] - Drug Profile 106
GVAX Prostate Cancer Vaccine - Drug Profile 107
TL-118 - Drug Profile 109
orteronel + [prednisone] - Drug Profile 111
mRNA- Transfected Dendritic Cells - Drug Profile 112
RG-7450 - Drug Profile 113
abiraterone acetate + [docetaxel] + [prednisone] - Drug Profile 114
CFG-920 - Drug Profile 116
Dendritic Cell Vaccination + [docetaxel] - Drug Profile 117
Androgen Receptor Antagonists - Drug Profile 118
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics - Drug Profile Updates 119
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics - Discontinued Products 162
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics - Dormant Products 163

Appendix 165
Methodology 165
Coverage 165
Secondary Research 165
Primary Research 165
Expert Panel Validation 165
Contact Us 166
Disclaimer 166

Number of Products Under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H1 2013 11
Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis, H1 2013 12
Number of Products under Development by Companies, H1 2013 14
Number of Products under Development by Companies, H1 2013 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2013 16
Comparative Analysis by Late Stage Development, H1 2013 17
Comparative Analysis by Mid Clinical Stage Development, H1 2013 18
Comparative Analysis by Early Clinical Stage Development, H1 2013 19
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 20
Products under Development by Companies, H1 2013 21
Products under Development by Companies, H1 2013 (Contd..1) 22
Products under Development by Companies, H1 2013 (Contd..2) 23
Products under Investigation by Universities/Institutes, H1 2013 24
Bristol-Myers Squibb Company, H1 2013 25
Johnson & Johnson, H1 2013 26
AstraZeneca PLC, H1 2013 27
Eli Lilly and Company, H1 2013 28
Genentech, Inc., H1 2013 29
Bavarian Nordic A/S, H1 2013 30
Merck & Co., Inc., H1 2013 31
Takeda Pharmaceutical Company Limited, H1 2013 32
Millennium Pharmaceuticals, Inc., H1 2013 33
Novartis AG, H1 2013 34
GTx, Inc., H1 2013 35
Teva Pharmaceutical Industries Limited, H1 2013 36
Progenics Pharmaceuticals, Inc., H1 2013 37
Exelixis, Inc., H1 2013 38
Aduro BioTech, H1 2013 39
Merck KGaA, H1 2013 40
Active Biotech AB, H1 2013 41
Oncothyreon Inc, H1 2013 42
Medivation, Inc., H1 2013 43
Oncogenex Pharmaceuticals, Inc., H1 2013 44
Synta Pharmaceuticals Corp., H1 2013 45
Nerviano Medical Sciences S.r.l., H1 2013 46
GenSpera, Inc., H1 2013 47
Bellicum Pharmaceuticals, Inc., H1 2013 48
TRACON Pharmaceuticals, Inc., H1 2013 49
Assessment by Monotherapy Products, H1 2013 50
Assessment by Combination Products, H1 2013 51
Assessment by Stage and Route of Administration, H1 2013 53
Assessment by Stage and Molecule Type, H1 2013 55
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics - Drug Profile Updates 121
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics - Discontinued Products 164
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics - Dormant Products 165
Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H1 2013 11
Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis, H1 2013 12
Products under Development by Companies, H1 2013 13
Products under Investigation by Universities/Institutes, H1 2013 16
Late Stage Products, H1 2013 17
Mid Clinical Stage Products, H1 2013 18
Early Clinical Stage Products, H1 2013 19
Pre-Clinical Stage Products, H1 2013 20
Assessment by Monotherapy Products, H1 2013 50
Assessment by Combination Products, H1 2013 51
Assessment by Route of Administration, H1 2013 52
Assessment by Stage and Route of Administration, H1 2013 53
Assessment by Molecule Type, H1 2013 54
Assessment by Stage and Molecule Type, H1 2013 55